20 February 2026 - Top Stories

Australia’s healthtech momentum is advancing on multiple fronts, from AI-driven pathology to cross-border digital care and public health collaboration.

In pathology, AI and data sharing are starting to reshape economics. Sonic Healthcare and Healius reported solid halves, with Sonic delivering revenue of A$5.445 billion (+17% year on year) and EBITDA of A$907 million, while Healius posted A$688.1 million revenue and A$122.2 million EBITDA. The sector’s direction is toward data-enabled models and direct-to-patient capabilities to preserve margins as automation and analytics become central to operational efficiency.

Australia is also pursuing a nationwide pathology exchange to boost real time data sharing. The push hinges on standardising data via the Fast Healthcare Interoperability Resources (FHIR) framework, under a broader National Healthcare Interoperability Plan led by the Australian Digital Health Agency. With dozens of laboratory information systems in play, the move aims to reduce delays and errors in public and private testing networks.

On the M&A front, US digital health group Hims & Hers is finalising the purchase of Australian telehealth firm Eucalyptus for up to USD 1.15 billion (about AUD 1.6 billion). Eucalyptus operates brands such as Pilot and Kin Fertility, and will continue serving Australian patients while aligning with Hims & Hers’ international platform. The deal signals a broader sweep of cross‑border digital clinics and heightened governance and data protection considerations.

Public health access is being expanded in Western Australia, where a A$2.6 million program will offer the Arexvy RSV vaccine free to residents aged 65 and older in aged care facilities. The subsidy, expected to reach around 15,000 people, removes a major cost barrier and could ease winter hospital admissions, serving as a model for subsidised vaccines in aged care.

Policy moves toward price transparency for specialist services are under way, with the government moving to mandate participation in the Medical Costs Finder. After a slow start, where around 1.4% of eligible specialists displayed fees, the reform aims to reduce cost barriers and support smarter pricing and data exchange across the care continuum.

In care delivery, interim evaluations of urgent care clinics show strong performance on safety and timeliness, with wait times around 13 minutes and a high proportion of staff rating care as safe and high quality. The findings highlight UCCs as a meaningful, though not sole, remedy for ED crowding and stress the need for funding models that integrate GPs and urgent care more effectively.

Meanwhile, the Pancreatic Cancer Early Detection Resources rollout brings new clinical tools and surveillance guides to help clinicians spot the disease earlier. With around 4,500 Australians diagnosed each year and five‑year survival near 14%, these resources aim to shift workflows, improve referrals and support palliative care planning as part of a broader early‑detection push.

• AI and data-enabled pathology are reshaping economics and care pathways.
• Nationwide pathology data exchange using FHIR standardises sharing across public and private labs.
• Hims & Hers acquires Eucalyptus, expanding cross-border digital clinics in Australia.
• WA subsidies RSV vaccination for aged care residents, boosting protection and potential hospital load relief.
• Mandatory price disclosure for specialists to enhance pricing transparency and data use in value-based care.
• Urgent care clinics demonstrate safe, timely care with potential to ease ED pressure in a constrained system.
• New resources for pancreatic cancer early detection aim to alter clinician workflows and referral pathways.